Filtered By:
Source: Neurology
Condition: Thrombosis

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 223 results found since Jan 2013.

HAT Score External Validity: A Predictor Of Hemorrhagic Transformation After Intravenous Thrombolysis (P3.107)
CONCLUSIONSThe consistency of the predictive capability of the scale in two great independent cohorts of t-PA-treated patients ( NINDS and HAT score ), and the presence of similar results in our cohort, indicate that this score is likely to have good external validity.Disclosure: Dr. Neto has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Neto, E. Tags: Cerebrovascular Disease and Interventional Neurology: t-PA Source Type: research

HAT Score Outperforms 7 Other Hemorrhagic Transformation Scores in Ischemic Stroke Patients Treated with Thrombolysis (P3.109)
Conclusions: HAT score yielded the highest odds ratio among the 4 scores that accurately predicted sICH in our independent dataset. HAT score also had low computational complexity compared to other scores. Our results demonstrate the potential utility of the HAT score as a predictor of adverse clinical outcome for acute ischemic stroke patients undergoing IV thrombolytic therapy.Disclosure: Dr. Asuzu has nothing to disclose. Dr. Nystrom has nothing to disclose. Dr. Halliday has nothing to disclose. Dr. Wira has nothing to disclose. Dr. Greer has nothing to disclose. Dr. Schindler has nothing to disclose. Dr. Sheth has rece...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Asuzu, D., Nystrom, K., Halliday, J., Wira, C., Greer, D., Schindler, J., Sheth, K. Tags: Cerebrovascular Disease and Interventional Neurology: t-PA Source Type: research

Rates of In-Hospital Adverse Events and Discharge Outcomes among Ischemic Stroke Patients Admitted to Joint Commission Primary Stroke Centers in United States (P3.122)
Conclusions: Patients admitted to PSCs are less likely to have in hospital adverse events and better discharge outcomes.Disclosure: Dr. Chaudry has nothing to disclose. Dr. Zafar has nothing to disclose. Dr. Reeves has nothing to disclose. Dr. Umair has nothing to disclose. Dr. Owais has nothing to disclose. Dr. Sachdeva has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Jani has nothing to disclose. Dr. Hussain has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Chaudry, S., Zafar, T., Afzal, M., Umair, M., Owais, M., Sachdeva, G., Adil, M., Jani, V., Hussain, S., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Primary and Comprehensive Stroke Centers Source Type: research

PFO Closure for Stroke Prevention. A Brief Meta-Analysis (P2.011)
CONCLUSIONS: This meta-analysis found benefit of PFO closure with the Amplatzer PFO Occluder in reducing tissue-defined recurrent ischemic stroke, but no statistically significant benefit in reducing TIA, study-defined ischemic stroke, or all-cause death.Disclosure: Dr. Latini has nothing to disclose. Dr. Saver has received personal compensation for activities with the University of California, BrainsGate, CoAxia, ev3, Talecris, PhotoThera, Sygnis, and Stryker. Dr. Saver has received research support from the University of California, and the National Institutes of Health.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Doldan, L., Latini, M., Saver, J. Tags: Cerebrovascular Disease and Interventional Neurology I Source Type: research

Stroke and Etonogestrel/Ethinyl Estradiol Ring (NuvaRing): Clinical, Radiological, and Prognostic Features. (P2.012)
Conclusions: In this largest case series of NuvaRing associated stroke to date, approximately half of the strokes are venous and half are arterial. Stroke typically occurred within the first year of use, and as soon as 2 weeks after NuvaRing initiation.Disclosure: Dr. Piran has nothing to disclose. Dr. Balucani has nothing to disclose. Dr. Tark has nothing to disclose. Dr. Adler has nothing to disclose. Dr. Levine has received personal compensation in an editorial capacity for MedLink. Dr. Levine has received royalty payments as editor of a book.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Piran, P., Balucani, C., Tark, B., Adler, Z., Levine, S. Tags: Cerebrovascular Disease and Interventional Neurology I Source Type: research

Identifying Barriers in Acute Stroke Therapy in Argentina. ARENAS Registry (P2.014)
CONCLUSIONS: Only 47% of patients were admitted to an Intensive Care Unit, rt-PA was underused and initial evaluation was not performed by a neurologist in most of cases. The gap between clinical practice guidelines and real world is wide in Argentina and interventions to improve acute stroke care are mandatory.Disclosure: Dr. Atallah has nothing to disclose. Dr. Fustinoni has nothing to disclose. Dr. Zurru has nothing to disclose. Dr. Beigelman has nothing to disclose. Dr. Cirio has nothing to disclose. Dr. Ameriso has nothing to disclose. Dr. Burry has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Atallah, A., Fustinoni, O., Zurru, M., Beigelman, R., Cirio, J., Ameriso, S., Burry, G. Tags: Cerebrovascular Disease and Interventional Neurology I Source Type: research

Prognostic Value of CT Angiography in the Hyperacute Phase of Middle Cerebral Artery Stroke. (P2.018)
CONCLUSION: CT and CTA hyperacute findings predicted volume of ischemic lesions and post stroke functional status in patients with MCAS.Disclosure: Dr. Santiago has nothing to disclose. Dr. Zurru has nothing to disclose. Dr. Luzzi has nothing to disclose. Dr. Brescacin has nothing to disclose. Dr. Alonzo has nothing to disclose. Dr. Camera has nothing to disclose. Dr. Waisman has nothing to disclose. Dr. Cristiano has received personal compensation for activities with Bayer Pharmaceuticals Corp., Biogen Idec, Merck & Co., Inc., and Novartis,
Source: Neurology - April 9, 2014 Category: Neurology Authors: Santiago, P., Zurru, M., Luzzi, A., Brescacin, L., Alonzo, C., Camera, L., Waisman, G., Cristiano, E. Tags: Cerebrovascular Disease and Interventional Neurology I Source Type: research

Utility of Workup for Thrombophilias in a Single Center - A Qualitative Perspective (P1.125)
ConclusionStroke is considered cryptogenic in about 30-40 percent cases. Hypercoagulable testing is often ordered in this clinical setting. So far our results are consistent with other reports in the literature that such testing has limited clinical utility. Our results highlight the need to develop stringent clinical guidelines for HT in the setting of ischemic strokes.Disclosure: Dr. Shah has nothing to disclose. Dr. Anderson has nothing to disclose. Dr. Drake has received personal compensation for activities with UCB Pharma as a speaker. Dr. Proytcheva has nothing to disclose. Dr. Coull has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Shah, A., Anderson, N., Drake, K., Proytcheva, M., Coull, B. Tags: Cerebrovascular Disease and Interventional Neurology: Ischemic Stroke Subtype Source Type: research

Etiology and the Cost of Pediatric Stroke (P2.106)
CONCLUSIONS: Our results likely capture the majority of costs during the year following an incident stroke. The disease associated with pediatric stroke significantly affects cost. Costs of childhood stroke care are significantly higher when the stroke occurs after the first month of life. Any future cost-benefit analyses of pediatric stroke treatment must include an analysis of stroke etiology and age of onset since they are major drivers of cost.Disclosure: Dr. Hamilton has nothing to disclose. Dr. Huang has nothing to disclose. Dr. Seiber has nothing to disclose. Dr. Lo has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Hamilton, W., Huang, H., Seiber, E., Lo, W. Tags: Cerebrovascular Disease and Interventional Neurology: Childhood and Young Adult Source Type: research

"Heparin-Less" Protocol for Endovascular Treatment of Acute Ischemic Stroke (P4.209)
Conclusions: We observed "heparin less" endovascular treatment results in high rates of recanalization with an acceptable rate of post thrombolytic ICH.Disclosure: Dr. Khan has nothing to disclose. Dr. Hassan has nothing to disclose. Dr. Zafar has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Khan, A., Hassan, A., Zafar, T., Malik, A., Adil, M., Suri, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Endovascular Source Type: research

Thrombus Density Predicts Successful Recanalization With Stent-Retriever Thrombectomy In Acute Ischemic Stroke (P4.215)
CONCLUSIONS In acute stroke treated with Solitaire stent-retriever thrombectomy, higher thrombus HU values are predictive of successful recanalization. Such information can be used in the decision-making process when estimating recanalization success rate with different endovascular treatment approaches.Disclosure: Dr. Mokin has received research support from Toshiba. Dr. Morr has nothing to disclose. Dr. Natarajan has nothing to disclose. Dr. Siddiqui has received personal compensation for activities with Codman & Shurtleff Inc., Concentric Medical, ev3/Covidien Vascular Therapies, Penumbra and Micrus Endovascular, Gu...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mokin, M., Morr, S., Natarajan, S., Siddiqui, A., Levy, E. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Endovascular Source Type: research

Are There Disparities in Thrombolytic Treatment and Mortality in Acute Ischemic Stroke in the Hispanic Population Living in Border States Versus Non-Border States? (P2.136)
Conclusions_ There was an underutilization of thrombolytics and higher mortality in the Hispanic population admitted in Border States but not in non-Border States. Further studies are warranted to better understand the associated factors.Disclosure: Dr. Hassan has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Zafar has nothing to disclose. Dr. Umair has nothing to disclose. Dr. Tekle has nothing to disclose. Dr. Sanchez has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Hassan, A., Adil, M., Zafar, T., Umair, M., Tekle, W., Sanchez, O., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Disparity Source Type: research

Etiologies of Neurologic Deterioration in the First 30 Days Following Ischemic Stroke (P3.091)
CONCLUSIONS: In the present study we found that Neurological worsening is not uncommon. There are various different etiologies and majorities of these can be controlled and treated with strict control and Close observation of these patients to prevent further worsening of Neurological status and ultimate disability.Disclosure: Dr. Ahmed has nothing to disclose. Dr. Hirni has nothing to disclose. Dr. Albadarin has nothing to disclose. Dr. Duggal has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ahmed, I., Hirni, K., Albadarin, S., Duggal, N. Tags: Cerebrovascular Disease and Interventional Neurology: Clinical Management Source Type: research

Stroke Outcomes and Usage of IV Alteplase during Pregnancy in the Nationwide Inpatient Sample 2005-2010 (P3.100)
ConclusionsStroke remains a serious complication in pregnancy, and mortality is increasing. Usage of tPA for AIS during pregnancy is minimal, with increased mortality compared to all strokes in pregnancy. Research efforts are needed to improve stroke outcomes during pregnancy.Disclosure: Dr. Ouyang has nothing to disclose. Dr. Knopf has nothing to disclose. Dr. Conners has nothing to disclose. Dr. Cutting has received personal compensation for activities with F1000. Dr. Lee has nothing to disclose. Dr. Smit has nothing to disclose. Dr. Kuklina has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Song, S., Ouyang, B., Knopf, T., Conners, J., Cutting, S., Lee, V., Smit, L., Kuklina, E. Tags: Cerebrovascular Disease and Interventional Neurology: t-PA Source Type: research

Baseline Body Temperature:Paradoxical Association with Severity and Non-Modification of Treatment Benefit in the NINDS TPA Stroke Trials (P3.101)
CONCLUSIONS: In hyperacute stroke patients, higher presenting temperatures are associated with less severe stroke deficits and final infarct volumes. Presenting temperature does not modify the benefit of tPA on good functional outcome at 3 months.Disclosure: Dr. Kim has nothing to disclose. Dr. Saver has received personal compensation for activities with the University of California, BrainsGate, CoAxia, ev3, Talecris, PhotoThera, Sygnis, and Stryker. Dr. Saver has received research support from the University of California, and the National Institutes of Health.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Kim, S. H., Saver, J. Tags: Cerebrovascular Disease and Interventional Neurology: t-PA Source Type: research